Skip to main content

Nafarelin Side Effects

Medically reviewed by Drugs.com. Last updated on Jul 24, 2023.

Applies to nafarelin: nasal spray.

Serious side effects of Nafarelin

Along with its needed effects, nafarelin may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking nafarelin:

More common

For adults (female)

For children (male)

For children (female)

Less common

Less common or rare

For adults (female)

Incidence not known

For adults (female)

Incidence not known

Other side effects of Nafarelin

Some side effects of nafarelin may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

For adults (female)

For children (male)

For children (female)

Less common or rare

For adults (female)

For children (male)

For children (female)

For Healthcare Professionals

Applies to nafarelin: nasal spray.

Cardiovascular

Very common (10% or more): Hot flashes/hot flush (up to 90%)

Common (1% to 10%): Chest pain, edema, hyper/hypotension

Frequency not reported: Palpitations

Postmarketing reports: Arterial thromboembolism, deep vein thrombosis, myocardial infarction, venous thromboembolism[Ref]

Hot flashes occurred commonly in adult women who were treated for endometriosis. Approximately 3% of children developed transient hot flashes.[Ref]

Psychiatric

Very common (10% or more): Decreased libido (up to 23%), emotional/affect lability (up to 15%)

Common (1% to 10%): Depression, increased libido, insomnia

Postmarketing reports: Aggression, anger, impatience, irritability, suicidal ideation, suicide attempt[Ref]

Genitourinary

Very common (10% or more): Vaginal dryness (up to 19%)

Common (1% to 10%): Transient breast enlargement, breast atrophy/decreased breast size, vulvovaginal dryness, artificial menopause, uterine hemorrhage, vaginal bleeding, white/brown vaginal discharge

Uncommon (0.1% to 1%): Ovarian cyst

Frequency not reported: Ovarian hyperstimulation syndrome[Ref]

Nervous system

Very common (10% or more): Headache (up to 18%)

Common (1% to 10%): Paresthesia

Frequency not reported: Migraines

Postmarketing reports: Convulsions, stroke, transient ischemic attack[Ref]

Dermatologic

Very common (10% or more): Acne (up to 14%)

Common (1% to 10%): Transient increase in pubic hair, body odor, seborrhea, pruritus, rash, urticaria, hirsutism

Uncommon (0.1% to 1%): Alopecia[Ref]

Respiratory

Common (1% to 10%): Rhinitis, dyspnea, nasal irritation

Frequency not reported: Shortness of breath

Postmarketing reports: Interstitial pneumonitis, pulmonary embolism, pulmonary fibrosis[Ref]

Musculoskeletal

Common (1% to 10%): Myalgia, decreased bone mineral density

Uncommon (0.1% to 1%): Arthralgia

Postmarketing reports: Arthritic symptoms[Ref]

Endocrine

Common (1% to 10%): Estrogen deficiency

Frequency not reported: Pituitary enlargement/asymmetry/pituitary gland changes (size and shape)

Postmarketing reports: Pituitary apoplexy[Ref]

Metabolic

Common (1% to 10%): Increased/decreased weight

Frequency not reported: Increased serum alkaline phosphatase, increased total cholesterol/triglycerides[Ref]

Hypersensitivity

Common (1% to 10%): Drug hypersensitivity[Ref]

Oncologic

A patient with congenital adrenal hyperplasia developed an adrenal rest tumor 8 months after discontinuing treatment; however, correlation to treatment is unlikely.

Pituitary gland adenomas have been observed in a few children receiving treatment; however, the relationship to treatment is unknown.[Ref]

Frequency not reported: Adrenal rest tumor of the testis, pituitary gland adenoma[Ref]

Hepatic

Frequency not reported: Increased AST/ALT, serious liver injury[Ref]

Ocular

Frequency not reported: Blurred vision[Ref]

Other

Postmarketing reports: Crying

References

1. Product Information. Synarel (nafarelin). Roche Laboratories. 2001;PROD.

2. Product Information. Synarel (nafarelin). Searle. PROD.

3. Product Information. Synarel (nafarelin). Pfizer U.S. Pharmaceuticals Group. 2022.

4. Cerner Multum, Inc. UK Summary of Product Characteristics.

5. Cerner Multum, Inc. Australian Product Information.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.